Literature DB >> 20413176

Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy.

U P Neumann, M Biermer, D Eurich, P Neuhaus, T Berg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20413176     DOI： 10.1016/j.jhep.2010.02.002

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  30 in total

1.  Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

Authors:  S DebRoy; N Hiraga; M Imamura; C N Hayes; S Akamatsu; L Canini; A S Perelson; R T Pohl; S Persiani; S L Uprichard; C Tateno; H Dahari; K Chayama
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

2.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

3.  Understanding silibinin's modes of action against HCV using viral kinetic modeling.

Authors:  Jeremie Guedj; Harel Dahari; Ralf T Pohl; Peter Ferenci; Alan S Perelson
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

4.  Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism.

Authors:  Janela McClure; Daciana H Margineantu; Ian R Sweet; Stephen J Polyak
Journal:  Virology       Date:  2013-11-27       Impact factor: 3.616

Review 5.  Silymarin for HCV infection.

Authors:  Stephen J Polyak; Nicholas H Oberlies; Eve-Isabelle Pécheur; Harel Dahari; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Antivir Ther       Date:  2012-09-25

6.  Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).

Authors:  Xuening Wang; Elzbieta Gocek; Victoria Novik; Jonathan S Harrison; Michael Danilenko; George P Studzinski
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

7.  Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.

Authors:  Katharina Esser-Nobis; Inés Romero-Brey; Tom M Ganten; Jérôme Gouttenoire; Christian Harak; Rahel Klein; Peter Schemmer; Marco Binder; Paul Schnitzler; Darius Moradpour; Ralf Bartenschlager; Stephen J Polyak; Wolfgang Stremmel; François Penin; Christoph Eisenbach; Volker Lohmann
Journal:  Hepatology       Date:  2013-02-07       Impact factor: 17.425

Review 8.  Management of hepatitis C infection before and after liver transplantation.

Authors:  Stefano Fagiuoli; Roberto Ravasio; Maria Grazia Lucà; Anna Baldan; Silvia Pecere; Alessandro Vitale; Luisa Pasulo
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 9.  Complementary and alternative medications in hepatitis C infection.

Authors:  Dina L Halegoua-De Marzio; Jonathan M Fenkel
Journal:  World J Hepatol       Date:  2014-01-27

Review 10.  Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

Authors:  Stephen J Polyak; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2013-03       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.